Live Breaking News & Updates on Rehan Verjee|Page 2

Stay updated with breaking news from Rehan verjee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Global Life Sciences Executive joins Bedford Group Transearch's Healthcare Advisory Board

/PRNewswire/ - Bedford Group Transearch Life Sciences is proud to announce Rehan Verjee has joined their North American Healthcare Advisory Board. "During a. ....

United States , United Kingdom , Jamie Condie , Darren Raycroft , Simon Pedder , Rehan Verjee , Howard Pezim , Tyra Biosciences , Cheryl Macdiarmid , University Of Oxford , Merck Kga , Healthcare Executive Committee , Merck Kgaa , Serono Inc Head Of The Innovative Medicine , Life Sciences , Bedford Group Transearch Life Sciences , Group Transearch Life Sciences , North American Healthcare Advisory , Advisory Board , Co Managing Director , North American Healthcare , Retired Former President , Senior Vice President , Global Commercial Strategy , Viiv Healthcare , Chief Marketing ,

Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare

Merck KGaA, Darmstadt, Germany, Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare
News provided by
Share this article
Share this article
DARMSTADT, Germany, Feb. 4, 2021 /PRNewswire/ Merck KGaA, Darmstadt, Germany, which operates its Healthcare business sector as EMD Serono in the US and Canada, today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine Franchises, to pursue an opportunity outside of the Company that will soon be announced. He will be succeeded by Andrew Paterson, who is currently Senior Vice President and Head of both the Global Multiple Sclerosis (MS) Franchise and the MS business unit in the United States. ....

United States , Merck Kga , Peter Guenter , Rehan Verjee , Andrew Paterson , Healthcare Executive Committee , Merck Kgaa , Group Website , Global Head , Innovative Medicine Franchises , Senior Vice President , Global Multiple Sclerosis , Healthcare Executive , Executive Board , Innovative Medicines , North American , Global Franchises , Global Neurology , Immunology Franchise , ஒன்றுபட்டது மாநிலங்களில் , மெர்க் க்க , ஆண்ட்ரூ பேட்டர்சன் , சுகாதாரம் நிர்வாகி குழு , குழு இணையதளம் , உலகளாவிய தலை , புதுமையானது மருந்து உரிமையாளர்கள் ,

European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

(PRNewsfoto/EMD Serono)
ROCKLAND, Mass. and NEW YORK, Jan. 25, 2021 /PRNewswire/ EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO
® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.
Avelumab is the only immunotherapy to demonstrate a significant improvement in overall survival in the first-line setting in a Phase III study in advanced or metastatic bladder cancer. With this approval by the European Commission, we can now offer patients a potential new first-line maintenance standard of care that may help them live longer, said Professor Thomas Powles, MD, Director of Barts Cancer Centre, London, UK. ....

United States , United Kingdom , City Of , Andy Schmeltz , Rehan Verjee , Thomas Powles , Pfizer Alliance , European Commission , Drug Administration , Group Website , Serono Inc , Merck Kga , Pfizer Inc , Merck Kgaa , Barts Cancer Centre , Professor Thomas Powles , Practice Guidelines , Global President , Global Head , Innovative Medicine Franchises , Safety Information , Approved Label , Stevens Johnson Syndrome , Medication Guide , Emd Serono , ஒன்றுபட்டது மாநிலங்களில் ,